Association between phthalate exposure and glutathione S-transferase M1 polymorphism in adenomyosis, leiomyoma and endometriosis

Po‐Chin Huang, Po-Chin Huang, Eing-Mei Tsai, Eing‐Mei Tsai, Wan-Fen Li, W.-F. Li, Pao‐Chi Liao, Pao-Chi Liao, Mu‐Chi Chung, Meng-Chu Chung, Youhua Wang, Ya-Hui Wang, Shu-Li Wang, Shu‐Li Wang
Human Reproduction · 2010 · vol. 25(4) , pp. 986–994 · doi:10.1093/humrep/deq015 · PMID:20147336 · W2147260640
article OA: bronze CC0 ⤵ 57 in-corpus citations
📄 Open PDF View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by claude@2026-06, 2026-06-06 ⓘ

This study found elevated urinary phthalate levels in women with leiomyoma and endometriosis, with GSTM1 null genotype increasing adenomyosis risk and interacting with phthalate exposure to raise risk for adenomyosis and leiomyoma.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

BACKGROUND: Phthalates are known to have estrogenic effects in cell models and experimental animals. However, the evidence regarding the effects of phthalates on human reproduction is still limited. We conducted a case-control study to determine whether estrogen-dependent diseases are associated with phthalate exposure and how the glutathione S-transferase M1 (GSTM1; a major detoxification enzyme) genotype modulates the risk. METHODS: We recruited subjects who underwent laparotomy and had pathologic confirmation of endometriosis (EN) (n = 28), adenomyosis (AD) (n = 16) and leiomyoma (LEI) (n = 36) from the Department of Obstetrics and Gynecology at a medical center in Taiwan between 2005 and 2007. Controls (n = 29) were patients without any of the three aforementioned gynecologic conditions. Urine samples were collected before surgery and analyzed for seven phthalate metabolites using liquid chromatography-tandem mass spectrometry. Peripheral lymphocytes were used for GSTM1 genotype determination. RESULTS: Patients with LEIs had significantly higher levels of total urinary mono-ethylhexyl phthalate (SigmaMEHP; 52.1 versus 18.9 microg/g creatinine, P < 0.05) than the controls, whereas patients with EN had an increased level of urinary mono-n-butyl phthalate (94.1 versus 58.0 microg/g creatinine, P < 0.05). Subjects with GSTM1 null genotype had significantly increased odds for AD relative to those with GSTM1 wild genotype [odds ratio (OR) = 5.30; 95% CI, 1.22-23.1], even after adjustment for age and phthalate exposure. Subjects who carried the GSTM1 null genotype and had a high urinary level of SigmaMEHP showed a significantly increased risk for AD (OR = 10.4; 95% CI, 1.26-85.0) and LEIs (OR = 5.93; 95% CI, 1.10-31.9) after adjustment for age, compared with those with GSTM1 wild-type and low urinary level of SigmaMEHP. CONCLUSIONS: These results suggest that both GSTM1 null and phthalate exposure are associated with AD and LEI. Larger studies are warranted to investigate potential interaction between GSTM1 null and phthalate exposure in the etiology of estrogen-dependent gynecologic conditions.

My notes (saved in your browser only)

Condition tags

endometriosisadenomyosis

MeSH descriptors

Endometriosis Glutathione Transferase Leiomyoma Phthalic Acids Uterine Neoplasms Adult Base Sequence Case-Control Studies DNA Primers DNA Primers Endometriosis Endometriosis Endometriosis Environmental Exposure Female Genotype Glutathione Transferase Humans Inactivation, Metabolic Leiomyoma

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (42)

Cited by (50)

Source provenance

europepmc
last seen: 2026-06-11T06:19:48.454388+00:00
openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pubmed
last seen: 2026-05-13T22:17:18.915199+00:00
License: CC0 · commercial use OK